Another aim of the current invention may include a recombinant cell-free expression system, the reaction mixture containing all the cell-free reaction components necessary for the in vitro biosynthesis of biological compounds, proteins, enzymes, biosimilars or chemical modification of small molecules.

The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

The present invention discloses rice serine hydroxymethyltransferase coded gene OsSHM4 mutants and application thereof. The rice serine hydroxymethyltransferase coded gene mutants are obtained in a manner that T at a 461st position of a CDS sequence region of a wild type rice OsSHM4 gene is mutated to C, so that coded amino acids thereof are mutated from leucine to proline. A CDS sequence of the wild type rice OsSHM4 gene is shown in SEQ ID NO. 1. After mutation of serine hydroxymethyltransferase coded genes OsSHM4, under a field experiment condition, S and Se content of rice shoots is remarkably improved without influencing biomass of rice. After wild type serine hydroxymethyltransferase coded genes OsSHM4 are genetically modified to complement the mutants, S and Se content of shoots of complemented strains is restored to that of wild type rice water planting.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

Provided are a microorganism for producing a pantoic acid, and a construction method therefor and an application thereof. The microorganism for producing the pantoic acid is obtained by knocking out a gene in Escherichia coli and introducing an exogenous gene. The obtained microorganism is Escherichia coli that is registered in the China General Microbiological Culture Collection Center with an accession number of CGMCC No. 21699. A pantoic acid synthesis pathway has been opened up, and accumulation of the pantoic acid can be achieved in a fermentation process.

A transgenic soybean plant resistant to soybean cyst nematode (SCN), or parts thereof, are provided. Also provided are methods of increasing SCN resistance of a soybean plant and associated DNA constructs.

The present invention relates to a recombinant microorganism, to a method for producing alanine and to the use of the recombinant microorganism for the fermentative production of alanine.